GlassScriptPhysician profile
Michael T Snyder
NPI 1871580639
$1,791.85
in general payments reported to CMS, 2019-2025
27 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $39.20 · 2021: $262 · 2022: $148 · 2023: $469 · 2024: $401 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $327.12 | 2019-2024 | Liletta, Lo Loestrin Fe |
| Amgen INC. | $282.20 | 2019-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $194.45 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $139.64 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Novo Nordisk INC | $135.42 | 2023-2025 | Wegovy |
| Mayne Pharma Commercial LLC | $99.57 | 2023-2025 | |
| Coopersurgical, INC. | $84.10 | 2021-2023 | Mara Console, Endosee |
| Sumitomo Pharma America, INC. | $65.67 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $63.75 | 2024 | |
| Pfizer INC. | $57.13 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.52 | 2023-2024 | |
| Organon LLC | $31.53 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $27.43 | 2019 | |
| Exact Sciences Corporation | $25.72 | 2024 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $21.17 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $21.11 | 2025 | Xt Cdx |
| Becton, Dickinson and Company | $19.28 | 2022 | |
| Lilly USA, LLC | $16.36 | 2025 | Zepbound |
| Covidien LP | $15.15 | 2020 | |
| Agile Therapeutics, INC. | $15.00 | 2021 | |
| Merck Sharp & Dohme LLC | $14.69 | 2024 | Gardasil, Gardasil 9 |
| Amag Pharmaceuticals, INC. | $14.60 | 2019 | |
| Medicem INC. | $14.32 | 2021 | |
| Sage Therapeutics, LLC | $13.86 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $13.23 | 2021 | |
| Exeltis, USA INC. | $12.86 | 2021 | |
| Sanofi Pasteur INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.